MedTrace Logo

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

NCT02727998 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-10-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to combine a single infusion of Ketamine with 7-days of trauma focus psychotherapy to relieve post traumatic stress disorder (PTSD) symptoms more effectively. This treatment has the potential to produce a significant therapeutic effect that otherwise would take months to occur.

Conditions

Interventions

DRUG

Ketamine

Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.

DRUG

Midazolam

Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Ilan Harpaz-Rotem, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2021-11-28
Completion
2021-11-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02727998 on ClinicalTrials.gov